Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage

Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Study ID
NCT06272565
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 90 Years
Healthy Volunteers
Not accepted

Study Details

Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients. This study aims to use a non-targeted metabolomics detection technique combined with ultra-high performance liquid chromatography time-of-flight mass spectrometry to analyze the metabolomics profile in aqueous humor sample of DR patents, and further explore the mechanism of the relationship between differential metabolites and their metabolic pathways with NLRP3 activation in DR inflammatory damage. DR patients with macular edema will receive anti-vascular endothelial growth factor (anti-VEGF) treatment; these patients will be divided into two groups: responders group and non-responders group.

Key Dates

First listed
Feb 22, 2024
Start date
Jul 3, 2024
Status verified
Jun 2024
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
240 participants (estimated)

Arms

  • Arm: CON(Non diabetes control group)
    Non diabetes patients undergoing phacoemulsification surgery
  • Arm: NDR(Non diabetes retinopathy diabetes patients)
    Non DR diabetes patients undergoing phacoemulsification surgery
  • Arm: NPDR (non proliferative diabetes retinopathy)
    DR patients with no sign of any neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery
  • Arm: PDR (proliferative diabetes retinopathy)
    DR patients with neovascularization suggested by fluorescein sodium angiography and receiving intravitreal injection surgery

Primary Outcome Measure

Untargeted metabolomics for metabolic profile using UHPLC/MS [ Time Frame: 24 weeks ]

Central Contacts

Find similar trials

Nationwide
Diabetic retinopathy trialsOphthalmology trialsRetina trials

Related Studies